US FDA, GSK put Avandia pharmacy exit plan in place
This article was originally published in Scrip
Executive Summary
As of 18 November, GlaxoSmithKline's once-top selling Type II diabetes drug Avandia (rosiglitazone), and its related products Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride), no longer will be available in US retail pharmacies, with the only access to the drugs available by mail order to patients already enrolled in a tightly controlled restricted access program, the US FDA and the company said on 18 May.